The established role of MMP-1 in cancer intravasation, coupled with our findings that MLK3 controls MMP-1 levels, prompted us to evaluate the components of the MLK3–FRA-1–MMP-1 signaling axis in CTCs. The gene discussed is MAP3K11; the disease is cancer.